DNA methylation profling identifes epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy

Carmen Sapienza, Jean Lee, Jasmine Powell, Oluwatoyin Erinle, Faahud Yafai, James Reichert, Elias S. Siraj, Michael Madaio

Research output: Contribution to journalArticle

128 Scopus citations

Abstract

We identified potential epigenetic biomarkers for chronic kidney disease progression by comparing site-specific DNA methylation levels in more than 14,000 genes between African American and Hispanic diabetes patients with end stage renal disease (ESRD) and diabetes patients without nephropathy. We identified 187 genes that are differentially methylated between the two groups on at least two CpG sites in each gene in DNA extracted from saliva. Of the 187 genes whose mean methylation levels differed between the two groups, 39 genes or closely related gene family members, have been reported to be involved in kidney development or diabetic nephropathy, per se, or have been associated with dialysis-induced changes in gene expression in peripheral blood cells. The fact that such a substantial fraction (21%) of the 187 candidate genes have been implicated previously through genome association or transcription profiling studies suggests strongly that the DNA methylation differences we observe are associated with disease predisposition and/ or treatment. The fact that these nephropathy and/or dialysis-associated differences between patients were identified in DNA extracted from saliva offers proof-of-principle that inter-individual epigenetic differences may prove useful as predictive biomarkers of disease susceptibility.

Original languageEnglish (US)
Pages (from-to)20-28
Number of pages9
JournalEpigenetics
Volume6
Issue number1
DOIs
StatePublished - Jan 2011

Keywords

  • Diabetic nephropathy
  • Dialysis
  • Dna methylation
  • End-stage renal disease

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'DNA methylation profling identifes epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy'. Together they form a unique fingerprint.

  • Cite this

    Sapienza, C., Lee, J., Powell, J., Erinle, O., Yafai, F., Reichert, J., Siraj, E. S., & Madaio, M. (2011). DNA methylation profling identifes epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics, 6(1), 20-28. https://doi.org/10.4161/epi.6.1.13362